Clinical, morphologic, cytogenetic, and mutation characteristics of adult AML cohort (N = 170 patients)
Characteristic . | Data . |
|---|---|
| Age, no. patients (%) | |
| Younger than 56 y | 34 (20) |
| 56 y or older | 136 (80) |
| Sex, no. patients (%) | |
| Female | 85 (50) |
| Male | 85 (50) |
| FAB classification, no. patients (%) | |
| M1 | 40 (24) |
| M2 | 60 (35) |
| M4 | 42 (25) |
| M5 | 13 (8) |
| M6 | 1 (1) |
| M7 | 2 (1) |
| M0 | 10 (6) |
| Other | 2 (1) |
| Evaluable cytogenics, no. patients (%) | |
| No | 29 (17) |
| Yes | 141 (83) |
| Cytogenetic risk category, no. patients (%)* | |
| Favorable | 12 (9) |
| Intermediate | 83 (59) |
| Unfavorable | 44 (31) |
| Not assigned | 2 (1) |
| Specific cytogenetic features, no. patients (%)† | |
| Normal | 65 (46) |
| t(8;21) | 8 (6) |
| inv(16) | 4 (3) |
| NPM1 mutation status, no. patients (%)‡; | |
| Type A | 45 (27) |
| Non-type A§ | 5 (3) |
| Type A or non-A | 50 (30) |
| FLT3 mutation status, no. patients (%)∥ | |
| ITD | 46 (27) |
| TKD | 13 (12) |
| Median age, y (range) | 65 (20-84) |
| Median WBC count, × 109/L (range) | 22.9 (0.7-272.5) |
| Median peripheral blasts, % (range) | 43 (0-99) |
| Median marrow blasts, % (range) | 70 (5-99) |
| Median platelet count, × 109/L (range) | 53 (2-1052) |
| Median hemoglobin level, g/dL (range) | 9.1 (4.3-14.4) |
Characteristic . | Data . |
|---|---|
| Age, no. patients (%) | |
| Younger than 56 y | 34 (20) |
| 56 y or older | 136 (80) |
| Sex, no. patients (%) | |
| Female | 85 (50) |
| Male | 85 (50) |
| FAB classification, no. patients (%) | |
| M1 | 40 (24) |
| M2 | 60 (35) |
| M4 | 42 (25) |
| M5 | 13 (8) |
| M6 | 1 (1) |
| M7 | 2 (1) |
| M0 | 10 (6) |
| Other | 2 (1) |
| Evaluable cytogenics, no. patients (%) | |
| No | 29 (17) |
| Yes | 141 (83) |
| Cytogenetic risk category, no. patients (%)* | |
| Favorable | 12 (9) |
| Intermediate | 83 (59) |
| Unfavorable | 44 (31) |
| Not assigned | 2 (1) |
| Specific cytogenetic features, no. patients (%)† | |
| Normal | 65 (46) |
| t(8;21) | 8 (6) |
| inv(16) | 4 (3) |
| NPM1 mutation status, no. patients (%)‡; | |
| Type A | 45 (27) |
| Non-type A§ | 5 (3) |
| Type A or non-A | 50 (30) |
| FLT3 mutation status, no. patients (%)∥ | |
| ITD | 46 (27) |
| TKD | 13 (12) |
| Median age, y (range) | 65 (20-84) |
| Median WBC count, × 109/L (range) | 22.9 (0.7-272.5) |
| Median peripheral blasts, % (range) | 43 (0-99) |
| Median marrow blasts, % (range) | 70 (5-99) |
| Median platelet count, × 109/L (range) | 53 (2-1052) |
| Median hemoglobin level, g/dL (range) | 9.1 (4.3-14.4) |
ITD indicates internal tandem duplication; TKD, point mutations of intracellular tyrosine-kinase domain.
To convert hemoglobin level from grams per deciliter to grams per liter, multiply grams per deciliter by 10.
n = 141. Cytogenetic risk categories are defined by the following cytogenetic abnormalities (abn): favorable: inv(16)/t(16;16)/del(16q), t(8;21), or t(15;17) with any additional abn; intermediate: +8, -Y, +6, del(12p), or normal karyotype; unfavorable; -5/del(5q), -7/del(7q), inv(3q), abn 11q, t(6;9), t(9;22), abn 17p, or complex karyotype defined as more than 3 abn. Other findings are listed as not assigned or nonevaluable.12
n = 141.
n = 165.
Non—type A includes 4 cases that hybridized to probes for 13 known variants (B to Q)26,44 and 1 case that was sequenced.
n = 105.